

INDEPENDENT RESEARCH
UPDATE


4th March 2016

Food & Beverages

Bloomberg	CPR IM
Reuters	CPR.MI
12-month High / Low (EUR)	8.4 / 6.1
Market capitalisation (EURm)	4,420
Enterprise Value (BG estimates EURm)	5,245
Avg. 6m daily volume ('000 shares)	1 687
Free Float	49.0%
3y EPS CAGR	12.8%
Gearing (12/14)	62%
Dividend yield (12/15e)	1.18%

Prices at 2nd March 2016

YE December	12/14	12/15	12/16e	12/17e
Revenue (EURm)	1,560	1,657	1,643	1,718
EBIT (EURm)	298.20	332.70	341.55	363.04
Basic EPS (EUR)	0.27	0.31	0.34	0.39
Diluted EPS (EUR)	0.27	0.30	0.33	0.38
EV/Sales	3.46x	3.17x	3.14x	2.95x
EV/EBITDA	16.0x	13.4x	13.2x	12.2x
EV/EBIT	18.1x	15.8x	15.1x	14.0x
P/E	28.7x	25.2x	22.9x	20.0x
ROCE	5.3	7.0	7.7	8.8



Campari

The wind in its sails

Fair Value EUR8,4 (price EUR7.61)

BUY

In the current environment, Campari has an ideal portfolio and geographic positioning. 2016 should be another strong year. We expect organic sales to rise 4.3% in 2016, accelerating vs. 2015, and EBIT margin to be up 70bps to 20.8%. Besides, the group has now the financial means to carry out acquisitions. We now have a Buy recommendation on the stock and a EUR8.4 fair value.

■ **A good portfolio.** The company is overexposed to bitters. We believe they account for c.30% of the group's sales while their weight in the other groups' sales is unlikely to exceed 2%. This unique positioning is really a major plus given the current consumption trends. Bitters are currently growing high single-digit. Campari is also the only European spirits group which has a bourbon, one of the most attractive whiskeys in the key US market.

■ **An attractive geographic profile.** Campari is underweight to the currently decelerating and highly volatile emerging markets. They account for only 25% of the group's sales vs 47% for Diageo, 40% for Pernod Ricard and 35% for Rémy Cointreau. Campari is also underexposed to the tough Travel Retail channel. We estimate that it accounts for 4% of the group's sales vs 9% for Rémy Cointreau, 7% for Pernod Ricard and 5% for Diageo.

■ **2016/2017 should see the return to the group's strategy of generating half of its growth through acquisitions.** Net debt declined EUR152m to EUR826m in 2015, exceeding our expectations (EUR888m) and implying a net debt/EBITDA ratio of 2.2x vs 2.9x in 2014. It can rise until 3.5x and even 4.25x for a limited period of time (18 months). We think that acquisitions should be well received by the market as the group's track record is good (Aperol, Wild Turkey, SKYY...).

■ **Estimates and valuation.** We expect organic sales to rise 4.3% in 2016, accelerating vs. 2015, and EBIT margin to be up 70bps to 20.8%. We reiterate our Buy recommendation. Our DCF points to a fair value of EUR8.4. At Wednesday's closing price, the stock is trading at 15.1x EV/EBIT 2016e and 14.0x EV/EBIT 2017e, 12% and 13% below the peer average.



Analyst:
Virginie Roumage
33(0) 1.56.68.75.22
vroumage@bryangarnier.com

Sector Analyst Team:
Nikolaas Faes
Loic Morvan
Antoine Parison
Cédric Rossi

Campari

Company description

Campari was founded in 1860 and today is the sixth-largest player worldwide in the spirits industry. The Group's portfolio, with over 50 brands, includes spirits, the core business, wines and soft drinks. Internationally-renowned brands include Aperol, Appleton, Campari, Cinzano, SKYY Vodka and Wild Turkey.

Simplified Profit & Loss Account (€m)	2012	2013	2014	2015	2016e	2017e
Net revenues	1,341	1,524	1,560	1,657	1,643	1,718
<i>Change (%)</i>	5.2%	13.7%	2.4%	6.2%	-0.8%	4.6%
Gross profit after distribution costs	770	810	832	917	921	969
Contribution after A&P	532	561	571	631	637	672
EBITDA	337	339	338	390	391	415
Result from recurring operations	305	300	298	333	342	363
<i>Change (%)</i>	2.0%	-1.6%	-0.5%	11.6%	2.7%	6.3%
Net financial income (charges)	(48.7)	(58.9)	(60.3)	(60.0)	(65.0)	(47.0)
Profit before taxes and non-controlling interests	236	230	194	249	277	316
Tax	(79.0)	(79.8)	(64.6)	(73.4)	(83.0)	(94.8)
Net profit	157	151	130	176	194	221
Minority interests	(0.50)	(0.60)	(0.60)	(0.60)	(0.60)	(0.60)
Group net profit	157	150	129	175	193	221
<i>Change (%)</i>	-1.6%	-4.3%	-13.9%	36.0%	10.0%	14.3%
Cash Flow Statement (€m)						
Operating cash flows	247	257	290	315	318	336
Change in working capital	(22.5)	(36.0)	(6.9)	(9.6)	(6.6)	(6.0)
Capex, net	(45.2)	(58.9)	(47.9)	(49.1)	(49.1)	(51.5)
Financial investments, net	(52.7)	(55.9)	(57.5)	(56.3)	(65.0)	(47.0)
Dividends	(40.5)	(39.8)	(46.1)	(45.7)	(52.2)	(52.2)
Other	(319)	(49.1)	(21.3)	(24.5)	(50.0)	(100)
Net debt	870	853	978	826	731	651
Free Cash flow	127	106	178	200	197	232
Balance Sheet (€m)						
Tangible fixed assets	390	397	436	445	449	451
Intangibles assets	1,664	1,582	1,872	1,932	1,932	1,932
Cash & equivalents	443	444	231	844	1,339	1,416
current assets	1,278	1,258	1,088	1,746	2,250	2,344
Other assets	70.5	65.3	119	101	(16.2)	(16.2)
Total assets	3,403	3,303	3,515	4,224	4,615	4,711
L & ST Debt	1,369	1,342	1,267	1,781	2,180	2,178
Others liabilities	601	564	667	687	566	523
Shareholders' funds	1,433	1,396	1,580	1,746	1,869	2,010
Total Liabilities	1,970	1,906	1,933	2,468	2,746	2,701
Capital employed	2,205	2,120	2,444	2,510	2,516	2,522
Ratios						
Gross margin	57.39	53.17	53.31	55.35	56.09	56.43
A&P as % of sales	17.69	16.35	16.72	17.28	17.30	17.30
Contribution after A&P as % of sales	39.70	36.82	36.60	38.07	38.79	39.13
Result from recurring operations	22.73	19.66	19.12	20.08	20.79	21.13
Tax rate	33.46	34.65	38.35	29.43	30.00	30.00
Net margin	11.68	9.84	8.27	10.59	11.75	12.84
ROE (after tax)	10.96	10.78	8.20	10.08	10.36	11.01
ROCE (after tax)	7.12	7.10	5.30	7.01	7.69	8.77
Gearing	60.69	61.08	61.93	48.63	(39.33)	(33.67)
Pay out ratio	25.93	32.00	30.17	29.78	27.06	26.30
Number of shares, diluted	587,200	590,855	582,346	580,296	580,296	580,296
Data per Share (€)						
Basic EPS	0.27	0.26	0.27	0.31	0.34	0.39
Diluted EPS	0.27	0.25	0.27	0.30	0.33	0.38
<i>% change</i>	0.0%	-7.4%	6.1%	14.0%	10.0%	14.3%
BVPS	2.44	2.36	2.71	3.01	3.22	3.46
Operating cash flows	0.42	0.43	0.50	0.54	0.55	0.58
Free Cash Flow	0.22	0.18	0.31	0.34	0.34	0.40
Net dividend	0.07	0.08	0.08	0.09	0.09	0.10

Source: Company Data; Bryan, Garnier & Co ests.

1. The company in brief

Fig. 1: Sales breakdown by region, 2015




Fig. 2: EBIT breakdown by region, 2015




Fig. 3: Sales breakdown between developed and emerging countries, 2015




Fig. 4: Sales breakdown by country, 2015




Fig. 5: Sales breakdown by segment, 2015





Fig. 6: Sales breakdown by brand, 2015



Sources: Campari; Bryan, Garnier & Co

2. A good portfolio positioning

2.1. Bitters: one of the keys to success

The bitters category is growing high single digit. It accounts for around 30% of Campari's sales compared with, according to our estimates, only 2% for its competitors Pernod Ricard and Diageo, respectively. The following table shows bitters brands owned by the spirit groups.

Fig. 7: Bitters brands by spirit group

CAMPARI	PERNOD RICARD	DIAGEO	REMY COINTREAU	BROWN-FORMAN
Campari	Ramazotti	Romana Sambuca		Tuaca
Aperol	Becherovka			
Campari Soda	Suze			
Cynar				
Averna				
Biancosarti				
Crodino				

Source: Companies

The group's two main competing brands in the bitters segment are Jägermeister (the only product of privately-held company Mast-Jägermeister) and Fernet Branca (owned by the Branca family). However, Campari offers two main advantages over these two companies:

- Its larger size allows for economies of scale in distribution and advertising expenses. Size is a key advantage for bitters –as with vodka– because they do not require ageing.
- The company controls around 90% of its distribution network.

Campari and Aperol are the group's flagship brands. They each represent one third of its bitter sales or 10% of its total sales. Aperol has a less bitter taste and a lower alcohol content than Campari, and these two distinctive features allow targeting younger consumers and women and competing with beer. Sales of Campari and Aperol respectively rose 6.1% and 11.8% organically in 2015.

The home markets of Campari/Aperol are improving. Germany is an important market for Aperol (25% of the brand's sales). The brand was very successful in this country, with 80% growth in 2011. Sales started to decline in Q4 2011 and kept on decreasing during 2012 and 2013. This fall can be explained by two main factors: the product was delisted by a key distributor and some me too's have been authorised. In 2015 Aperol finally stabilized, enabling sales in Germany to grow 3.2% organically. The group said it expects a low single digit sales growth in the country in 2016 (our estimate: +3%). Following the improvement of Aperol, next year should see the return to growth of Campari behind a new campaign. Italy is expected to accelerate next year: we expect organic sales in the country to grow 2%, in line with Campari's guidance (low single digit growth).

But there is also a strong potential for bitters in new geographies, what Campari called its seeding markets. In 2015, the sales growth of Aperol was impressive in France (+96%), Spain (+119%), and the UK (+233%). This reflects the craze for Aperol Spritz cocktail, whose main ingredient is Aperol. This cocktail is very easy to prepare and much cheaper (between EUR0.80 and

EUR0.90 a glass) than competing drinks (for example, a mojito is twice as expensive). In the US, sales of Campari grew 27.7% organically last year, driven by the craze for Italian specialties and traditional cocktails (Negroni is made with Campari). The seeding markets should accelerate in 2016 thanks to innovations and marketing investments.

2.2. The bourbon Wild Turkey: another strong asset

In the United States, whiskeys are growing very strongly and bourbon/Tennessee is one of the best performing segments.

Fig. 8: Whiskeys/Vodka: sales value growth






Fig. 9: Sales value growth by whisk(e)y category



Source: DISCUS

Campari is the only European spirit group to have a strong bourbon brand, i.e Wild Turkey (8% of the group’s sales or 25% of the US sales). The brand’s sales in the United States rose 7.6% organically in 2015, strongly accelerating vs. 2014 when they were flattish. Globally, Wild Turkey posted an 8.8% organic sales growth last year and the group expects an acceleration in 2016.

Fig. 10: Weight of bourbon/Tennessee as % of US sales



Sources: Companies Data; Bryan, Garnier & Co ests.

3. An attractive geographic exposure

The group's geographic exposure is an asset in the current context.

Yesterday, Brown-Forman has revised its 2016 guidance. It now expects:


- Organic sales growth of around 5% vs. 6-7% previously;
- Organic operating income of 7-9% vs. 8-10% previously.

The US group said that it was due to:

- Deteriorating emerging markets as weaker economic conditions and further devaluations of local currencies negatively impacted underlying demand. Organic net sales in EMs grew 5% over the 9M but they grew only 1% in Q3. Brazil, Turkey, Mexico and South Africa all delivered solid YTD organic sales growth, while markets such as Poland, Russia, Southeast Asia, emerging Africa and other EMs in South America declined in Q3.
- Softness in the global travel retail channel, partly reflecting the decrease of Russian travelers and the Paris attacks.

Campari is underweight to the emerging markets. They account for only 25% of the group's sales vs. 47% for Diageo, 40% for Pernod Ricard and 35% for Rémy Cointreau. **Campari is also underexposed to the Travel Retail channel.** We estimate that it accounts for 2% of the group's sales vs. 9% for Rémy Cointreau, 7% for Pernod Ricard and 5% for Diageo.

Fig. 11: Sales breakdown between developed and emerging countries, 2015



Sources: Companies; Bryan, Garnier & Co

4. Acquisitions as growth drivers

4.1. A good track record

The group features a strict financial discipline in terms of acquisitions. Since 2001, Campari has spent EUR1.9bn in acquisitions, without ever paying too much. Based on its track record, the group has carried out acquisitions at an average EV/EBITDA multiple of 11.1x. Its most expensive acquisitions were those of Lascelles deMercado in 2012 (15x) and Forty Creek Distillery (14.5x), which were partly justified by the strong growth potential of these two brands and by the need to complement the group’s portfolio with new categories (rum and Canadian whiskey).

Fig. 13: Campari’s acquisitions

Year	Target	Amount	EV/EBITDA
2001	Skyy Spirits	EUR399m	10.8x
2003	Barbero 1891 (Aperol)	EUR147.1m	11.6x
2005	Glen Grant, Braemar brands, Old Smuggler	EUR130m	6.6x
2007	Cabo Wabo Tequila	EUR75m	11.8x
2008	Destiladora San Nicolas	EUR22.2m	10x
2009	Wild Turkey	EUR418.4m	12x
2010	Carolans, Frangelico, Irish Mist	EUR128.2m	7.5x
2011	Sagatiba	EUR26.1m	13x
2012	Lascelles deMercado	EUR330m	15x
2014	Forty Creek Distillery	EUR120.5m	14.5x
2014	Fratelli Aversa	EUR103.7m	9.2x
2001-2014	Total amount spent	EUR1.9bn	Average: 11.1x

Sources: Companies, Bryan, Garnier & Co

As shown in the table below, the average price paid by Campari is 30% lower than sector average (EV/EBITDA multiple of 15.9x). It should be noted that we excluded acquisitions in the wine and soft drinks segments from our sample.

Fig. 14: Major acquisitions in the spirits sector

Year	Acquirer	Target	EV/EBITDA
2001	Diageo / Pernod Ricard	Seagram	15x
2005	Pernod Ricard / Fortune Brands	Allied Domecq	10x
2006	Brown-Forman	Casa Herradura	22x
2008	Pernod Ricard	Vin&Sprit	21x
2009	Campari	Wild Turkey	12x
2010	Campari	C&C Spirits & Liqueurs business	7.5x
2011	Diageo	Mey Icki	9.9x
2012	Diageo	Ypioca	17x
2012	Rémy Cointreau	Bruichladdich	24x
2012	Beam	Pinnacle Vodka	17x
2012	Campari	Lascelles de Mercado	15x
2013	Suntory	Beam	20x
		Average	15.9x

Sources: Companies, Bryan, Garnier & Co

The group's prudent approach can be explained by three factors:

- The involvement of the Garavoglia family, holding a 51% stake in the company's share capital and voting rights;
- The size of the group (medium) with a market capitalisation of EUR4.4bn;
- A wise target selection: Campari seeks to acquire brands that fall within one of the two following categories and are therefore affordable:
 - ✓ "Hidden gems": brands that have existed for a long time but have been neglected by their owners for a while;
 - ✓ "Rising stars": they post substantial growth rates but they have not achieved their full potential yet, in terms of geographical coverage or brand recognition.

The group's acquisitions are also strategically consistent. In terms of acquisitions, Campari has the following three objectives:

- Generating sales and cost synergies in the group's current markets, in particular through economies of scale;
- Acquiring established platforms in new regions or countries where the group will be able to expand its existing brands;
- Adding strong and complementary brands to its portfolio.

The group carefully selects its targets and its acquisitions are always based on a strong rationale.

Fig. 15: Group's acquisitions and their rationale


Year	Target	Rationale
2001	Skyy Spirits	Exposure to the US and to the vodka category
2003	Barbero 1891 (Aperol)	Exposure to a medium-alcoholic content spirit (Aperol)
2005	Glen Grant, Braemar brands, Old Smuggler	Exposure to the whiskey category
2007	Cabo Wabo Tequila	Strengthened presence in the US and exposure to tequila
2008	Destiladora San Nicolas	Access to the Mexican market
2009	Wild Turkey	Presence in the bourbon category and basis for its own distribution platform in Australia
2010	Carolans, Frangelico, Irish Mist	Strengthened presence in the US
2011	Sagatiba	Exposure to cachaça and Brazil
2012	Lascelles deMercado	Exposure to rum
2014	Forty Creek Distillery	Exposure to Canadian whisky
2014	Fratelli Averna	Increased critical mass in Central Europe

Sources: Campari, Bryan, Garnier & Co

4.2. Further acquisitions are expected

Campari has a strong financial structure. The group was constrained following the acquisitions of Forty Creek and Fratelli Averna in 2014. In 2015 it reduced its net debt by EUR152m to EUR826m, exceeding our expectations (EUR888m) and implying a net debt/EBITDA ratio of 2.2x vs. 2.9x in 2014. **This will enable the group to return to its previous strategy of generating half of its growth through acquisitions.**

Fig. 16: Net debt and net debt/EBITDA ratio



Sources: Campari, Bryan, Garnier & Co

The group has to maintain its net debt/EBITDA ratio under 3.5x. The following simulation seeks to determine the maximum size of a potential target for 2016 and 2017. We consider that any acquisition will have to be paid for in cash or funded with new debt and we subsequently exclude the scenario of a capital increase.

Fig. 17: Simulation of the group's borrowing capacity

EURm	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5
Assumption of sales	50	100	200	300	400
Average EBITDA margin	25%	25%	25%	25%	25%
EBITDA	12,5	25	50	75	100
2016					
Sector's average 2016e EV/sales			4,2x		
EV of the target	210	420	840	1260	1680
Net debt (EV of the target + Campari's net debt)	945	1155	1575	1995	2415
Consolidated EBITDA	405	417	442	467	492
Net debt/EBITDA	2,3	2,8	3,6	4,3	4,9
2017					
Sector's average 2017e EV/sales			4.0x		
EV of the target	200	400	800	1200	1600
Net debt (EV of the target + Campari's net debt)	877	1077	1477	1877	2277
Consolidated EBITDA	429	441	466	491	516
Net debt/EBITDA	2,0	2,4	3,2	3,8	4,4

Sources: Campari, Bryan, Garnier & Co


This simulation (which does not take into account potential synergies or acquisitions in the wine and soft drinks sector) shows that in 2016, only scenarios 1 and 2 will enable the group to comply with its banking covenant of a net debt/EBITDA ratio under 3.5x. In 2017, the group will be able to acquire a target having a maximum size of EUR200m. It should be noted that Campari is allowed to exceed the 3.5x ratio for a limited period of time (can be raised to 4.25x for 18 months). Therefore, scenarios 3 in 2016 and 4 in 2017 cannot be excluded.

Since Campari still has room to carry out acquisitions, which brands would be attractive potential targets? The group clearly targets the United States. Of note, the group acquired the distribution rights for Bulldog Gin in November 2013 and has a call option on this brand starting in 2020.

5. Another strong year in 2016

We expect 4.3% organic sales growth in 2016, ahead of the 2015 trend (+3%). This acceleration should be driven by 1/ Southern Europe/Middle East/Africa which should benefit from a return to growth in Italy (low single digit expected following a flattish performance in 2015) and continued good momentum in the seeding markets and 2/ North/Central/Eastern Europe with less drag coming from Russia (high single digit drop expected in 2016 vs -41% in 2015).


Fig. 18: Organic sales growth



Sources: Campari, Bryan, Garnier & Co

The EBIT margin should continue to increase in 2016 (+70bps to 20.8%) thanks to the positive sales mix arising from growth in the global priorities and especially the bitters (Aperol and Campari) and Wild Turkey. It should be noted that the gross margin of the global priorities is 70% vs. 55% for the group's average. The group has also indicated that the cash tax rate in 2016 fall to 23% due to the geographical mix. Overall the EPS should increase by 12% each year on average between 2015 and 2018.

Fig. 19: EBIT margin



Sources: Campari, Bryan, Garnier & Co

6. Valuation

Our DCF points to a fair value of EUR8.4.

Fig. 20: DCF (1)

	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e
Sales	1 643,0	1 718,0	1 801,9	1 895,3	1 999,3	2 094,9	2 180,5	2 254,3	2 314,8	2 360,8
% change	-0,3%	4,6%	4,9%	5,2%	5,5%	4,8%	4,1%	3,4%	2,7%	2,0%
EBIT	341,0	363,0	385,6	409,4	435,8	456,7	481,9	504,9	525,4	543,0
EBIT margin	20,8%	21,1%	21,4%	21,6%	21,8%	21,8%	22,1%	22,4%	22,7%	23,0%
-income taxes	-83,3	-95,2	-96,4	-102,3	-109,0	-114,2	-120,5	-126,2	-131,4	-135,7
+ depreciation	49,5	51,8	54,3	57,2	60,3	63,2	65,8	68,0	69,8	71,2
as % of sales	3,0%	3,0%	3,0%	3,0%	3,0%	3,0%	3,0%	3,0%	3,0%	3,0%
+ change in WC	-9,6	-10,0	-12,6	-13,3	-14,0	-14,7	-15,3	-15,8	-16,2	-16,5
as % of sales	-0,6%	-0,6%	-0,7%	-0,7%	-0,7%	-0,7%	-0,7%	-0,7%	-0,7%	-0,7%
Operating cash flows	297,6	309,6	330,9	350,9	373,2	391,0	411,9	430,9	447,7	461,9
-capex	-49,1	-51,8	-54,3	-57,2	-60,3	-63,2	-65,8	-68,0	-69,8	-71,2
as % of sales	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%	-3,0%
Free cash flow	248,5	257,8	276,6	293,8	312,9	327,8	346,1	362,9	377,9	390,7
Discount coefficient	0,93	0,87	0,81	0,75	0,70	0,65	0,61	0,56	0,53	0,49
Discounted FCF	231,4	223,4	223,2	220,7	218,8	213,4	209,8	204,8	198,5	191,0

Sources: Campari, Bryan, Garnier & Co

Fig. 21: DCF (2)

Sum of discounted FCF	2135
+Terminal value	3597
+Financial assets	10
-Net debt	-826
-Minorities	0
-Provisions	-24
Equity value	4893
Number of shares (m)	580
Fair value (EUR)	8,4

Sources: Campari, Bryan, Garnier & Co

At Wednesday's closing price, the stock is trading at 15.1x EV/EBIT 2016e and 14.0x EV/EBIT 2017e, 12% and 13% below the peer average.


Fig. 22: Tableau de multiples

	2016e EV/EBIT (x)	2017e EV/EBIT (x)	2016e premium/discount	2017e premium/discount
Campari	15,1	14,0	-12%	-13%
Diageo	18,6	17,9	8%	11%
Pernod Ricard	15,1	14,4	-12%	-11%
Rémy Cointreau	20,1	18,1	17%	12%
Average	17,2	16,1		

Sources: Campari, Bryan, Garnier & Co

Price Chart and Rating History

Campari



Ratings

Date	Ratings	Price
02/03/16	BUY	EUR7.51
12/11/15	SELL	EUR8
17/09/14	NEUTRAL	EUR5.8

Target Price

Date	Target price
02/03/16	EUR8.4
13/05/15	EUR7.1
08/04/15	EUR7
11/02/15	EUR6.4
08/01/15	EUR6.2
09/12/14	EUR5.8
13/11/14	EUR5.9
17/09/14	EUR6

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 63,4%

NEUTRAL ratings 29,1%

SELL ratings 7,5%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

Summary of Investment Research Conflict Management Policy is available www.bryangarnier.com



BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.